查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1853475

次要大麻素市场按产品类型、用途、形态、分销管道、最终用途产业和萃取方法划分－2025-2032年全球预测

Minor Cannabinoids Market by Product Type, Application, Form, Distribution Channel, End Use Industry, Extraction Method - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，次要大麻素市场将成长至 358.6 亿美元，复合年增长率为 8.41%。

主要市场统计数据
基准年 2024 187.9亿美元
预计年份：2025年 203.9亿美元
预测年份：2032年 358.6亿美元
复合年增长率 (%) 8.41%

次要大麻素已从主流大麻素的阴影中脱颖而出，成为科学研究和商业性实验中一个独特的领域。这些化合物在大麻植物中的含量较低，因其独特的药理作用、感官特性和产品创新潜力而备受关注。随着研究的深入以及萃取和製剂技术的进步，开发人员、临床医生和消费品牌纷纷涌向这些领域，寻求利用次要大麻素的微妙作用。

分析化学和标靶萃取技术的最新进展降低了分离大麻酚和大麻色烯等化合物的技术门槛，而临床上重新燃起的兴趣也促使人们对治疗机制进行更深入的研究。同时，消费者对主流大麻素替代品的好奇心，正在催生定位于健康、治疗和休閒领域的新产品。随着智慧财产权、供应链韧性和监管政策的清晰度成为关键的竞争因素，投资者和策略买家正密切关注这些领域。

因此，各公司正优先考虑将科学检验、合规的商业化管道和差异化品牌结合的跨职能策略。有效进入市场需要研发、监管、生产和开发等各职能部门的协同努力，该领域正从手工实验转向结构化的产品开发和机构投资。

科学进步、监管调整和不断变化的消费者期望如何汇聚，从而改变各行业的商业化轨迹和策略重点？

在科学进步、监管变革和消费者需求三者共同推动下，大麻产业正经历变革性的转变。在科学方面，分析方法和精密萃取技术的进步使得人们能够鑑定和分离出比以往更广泛的微量大麻素，从而揭示出不同的受体相互作用和治疗假设。因此，研究计画正从合法的大麻素扩展到那些具有更微妙或互补生物效应的分子。

监管环境也在不断变化，各地都在调整监管框架，以适应新的大麻素，调整标籤和检测要求，并在公共卫生问题和商业性机会之间取得平衡。这些监管调整迫使企业加大合规基础建设投入，并设计能够经受更严格审查的产品。同时，消费者的行为也不断演变。注重健康和治疗的成熟消费者都要求产品具有针对性配方、来源透明且有科学根据。

为此，现有企业和新参与企业都在不断完善打入市场策略，强调证据、供应链可追溯性和差异化的产品叙事。投资者也越来越关注那些能够证明其提取流程可重复、分析测试可靠且监管管道清晰的公司。总而言之，这些发展正在加速该领域从探索性应用案例向结构化、可扩展的商业化模式的成熟化进程。

2025年美国关税调整对小宗大麻素价值链的筹资策略、供应链韧性与製造伙伴关係的影响

美国关税政策在2025年前的调整正在重塑跨境供应链的经济格局，迫使企业重新评估其采购和生产布局。以往依赖国际提领、配方和原料供应的企业，如今正根据影响植物原料、纯化分离物和成品原料流通的关税变化，重新计算到岸成本、前置作业时间和库存策略。

为因应这些贸易动态，许多企业正在加快近岸外包步伐，优先发展国内资源开采能力，或实现供应商网路多元化，以降低单一来源风险。这些调整不仅出于成本考量，更体现了供应链韧性、品管和监管合规方面的战略意义，尤其是在各国监管机构加强对检验结果和原产地证明文件的审查之际。此外，拥有垂直整合营运模式的企业能够更好地抵御关税的影响，因为它们可以内部创造价值并利用内部合规能力。

此外，关税环境也正在影响伙伴关係模式。契约製造和加工商正在重新评估其服务内容，以帮助面临贸易成本不断上涨的跨国客户。策略性买家、授权人和合资伙伴正在评估联合生产投资能否在保持产品快速上市的同时抵消关税风险。因此，企业主管必须将关税情境纳入采购决策和应急计划，以便在贸易经济格局变化时保持灵活应对。

一个全面的细分框架揭示了产品类型、应用形式、分销管道和最终用途提取方法如何决定策略产品和监管选择。

按产品类型细分，可以明确大麻色烯、大麻酚、大麻酚、Δ-8-四氢大麻酚 (THC) 和四氢大麻酚 (THCV) 的科学和商业性考量，每种成分都具有独特的药理学特性，可为配方策略和监管风险评估提供依据。同样，按应用领域进行细分，可以区分临床证据要点和消费者定位。医疗应用涵盖神经病变、疼痛管理、皮肤疾病和睡眠障碍；娱乐应用着重于休閒娱乐和感官增强；而健康应用则着重于膳食补充剂、健身恢復和压力缓解。这些应用领域直接影响产品宣称的建置、证据要求和通路适用性。

饮料、偏好、油剂、酊剂和外用製剂在配方、稳定性和剂量方面各有不同，面临不同的挑战。在饮料领域，能量饮料、浸泡水和茶等细分产品需要专注于溶解度和感官遮罩。烘焙点心、巧克力和软糖等偏好产品需要完善的稳定性通讯协定和稳定的活性成分分布。膏霜、乳霜和乳液等外用製剂则必须考虑皮肤吸收和防腐系统。分销管道细分区分了不同的消费者管道，从包括成人用药房、持证零售店和医疗经销店在内的药房，到以直接面向消费者和市场策略为中心的电子商务模式，再到医院和药房。

依最终用途产业划分，化妆品可细分为护髮、彩妆和护肤；食品饮料可细分为食品饮料、糖果甜点和零嘴零食；营养保健品可细分为机能性食品和膳食补充剂；个人护理和药品可细分为非处方药和处方药管道。最后，按萃取方法划分——亚临界和超临界二氧化碳萃取、乙醇萃取、丁烷或丙烷烃萃取以及机械萃取——决定了成本结构、杂质谱和可扩展性。这些细分视角构成了一个多维框架，用于指南微量大麻素生态系统中的产品开发、监管策略和商业性优先排序。

美洲、欧洲、中东和非洲以及亚太地区的区域动态和监管差异，决定了商业化和合规策略的差异性。

美洲、欧洲、中东和非洲以及亚太地区的区域驱动因素正在塑造各自不同的研发、监管和商业化路径，分别代表不同的投资者情绪、消费者偏好和政策环境。在美洲，成熟市场与快速发展的州级法规相结合，推动着治疗和成人用药领域的创新，而商业化相关人员则专注于优化检测基础设施、供应链可追溯性和零售管道。

在欧洲、中东和非洲，监管环境的多样性和较保守的公共卫生框架通常要求提供严格的临床证据和明确的产品定义。面向这些市场的上市公司专注于药物研发路径、医疗产品註册以及与成熟医疗机构的合作。相较之下，亚太地区情况复杂，文化态度、进口法规和对大麻素产品的容忍度各不相同，因此需要精心製定市场策略。许多公司优先考虑与当地经销商伙伴关係，按照区域成分标准配製产品，并设计教育计画以建立消费者信任。

综上所述，这些区域性洞察表明，成功的市场策略应将本地监管资讯与灵活的生产和分销模式相结合。策略性参与企业应投资于区域合规、必要的本地临床和安全测试，以及符合当地文化的行销，以加速产品推广，同时降低监管和声誉风险。

决定市场领导地位的主要企业的能力和竞争优势，包括萃取技术、配方可扩展性、监管参与度和分销网络。

在次要大麻素市场，企业在研发、萃取、配方、监管和分销等方面的能力决定了其竞争地位。主要企业凭藉专有的提取技术、检验的分析方法以及将分子特征转化为稳定、可重复产品的卓越能力脱颖而出。对于寻求临床检验和机制研究以支持可靠产品声明的企业而言，与学术研究机构和合约研究机构建立合作关係日益普遍。

生产能力仍然是一项战略差异化因素，能够扩大二氧化碳或乙醇萃取规模，同时保持严格的杂质监测和批次重复性的公司拥有战术性优势。同时，拥有弹性配方平台（可满足饮料、偏好製剂和口服製剂等多种应用需求）的公司更能适应不断变化的消费者偏好。分销实力，无论是透过授权、药房管道还是强大的直销电商模式，都能帮助参与企业更快地将产品推向市场，并获取数据以进行迭代产品改进，从而实现差异化竞争。

智慧财产权和监管备案进一步拉开了市场领导者与新兴竞争对手之间的差距。将可防御的製程智慧财产权与积极主动的监管沟通结合的企业，能够更快地获得新产品核准并降低商业风险。这些能力共同构成了策略联盟、併购和授权交易的基础。

产业领导者可采取的可操作策略重点是将科学差异化与具有韧性的供应链相容的商业化以及值得信赖的消费者提案结合。

为了将技术潜力转化为商业性成果，产业领导者应优先考虑整合科学检验、合规生产和消费者教育的整合策略。首先，他们投资于严谨的分析和临床前研究，以确保产品的可重复性并阐明其作用机制。这些数据资产有助于与临床研究人员和医疗保健相关人员建立伙伴关係，同时也能为可信赖的市场宣传提供支持，并减少监管方面的阻力。

第二，我们将实现萃取和生产布局的多元化，以平衡成本效益和供应链韧性。近岸外包、双重采购以及对可扩展的二氧化碳和乙醇平台的投资将有助于降低贸易风险，并确保产品品质的稳定性。第三，我们将采取针对不同管道的商业化策略。我们将根据药房和医疗管道的要求，设计符合实证要求的配方和标籤；同时，我们将针对直接面向消费者和零售管道，量身定制健康和休閒产品，优先考虑用户体验和便利性。

第四，建构监管情报能力，以预测政策变化并积极与监管机构和标准制定机构互动。最后，透过透明的采购资讯揭露、第三方检测以及将科学发现转化为实际利益的消费者教育项目，建立品牌信任。透过整合这些策略支柱，企业可以将自身的技术差异转化为广泛的市场地位和永续成长。

透过整合相关人员访谈、技术文献研究以及监管审查和综合分析等稳健的混合方法研究途径，获得可操作的营运和策略洞察。

本分析的调查方法结合了对行业相关人员的定性访谈、文献综述以及对公开监管指南和同行评审文献的技术审查。主要访谈包括与研发负责人、供应链高管、监管专家和商业策略家进行结构化对话，以了解当前营运挑战和不断变化的优先事项。这些对话旨在就提取选择、配方限制和市场推广权衡等方面获得可操作的见解。

辅助资料来源包括近期发表的关于大麻素药理学的同行评审研究、分析实验室发布的关于检测和稳定性方法的白皮书，以及有关产品分类和标籤的司法管辖区政策更新。此外，还对提取平台和生产流程进行了技术评估，以评估规模、成本驱动因素和杂质控制要求。对于已发表证据有不足之处的情况，我们进行了专家三角验证，以提供解释性背景和风险框架。

贯穿始终，该方法优先考虑对假设进行透明记录，并对新出现的科学讯号进行保守解读。因此，此综合分析强调了营运考量、监管管道和策略影响，而非商业性推测，从而确保建议以可操作且可观察的产业实践为依据。

结论强调，在不断变化的环境中，需要科学严谨性、营运韧性和因地制宜的商业化策略来抓住机会。

总之，次要大麻素是一个复杂且快速发展的领域，科学发现、监管合规和消费者需求在此交会融合，共同打造差异化的商业性管道。为了使这一领域成熟，企业必须投资于严谨的分析能力、稳健的供应链以及符合当地法律规范和通路预期的打入市场策略。那些能够获得可靠的科学检验并展现生产一致性的企业，将更有能力将其技术优势转化为持久的品牌价值。

此外，积极与监管机构沟通以及采取多元化的筹资策略对于应对贸易动态和政策不确定性至关重要。将科研机构和商业性伙伴聚集在一起的合作模式可以加速证据生成，同时分散研发风险。最后，清晰的消费者教育和透明的品质保证措施对于建立信任以及促进产品在医疗、健康和休閒等不同应用情境中的广泛应用至关重要。

随着次要大麻素生态系统的不断发展，那些采用综合方法，将研究的严谨性、运营的韧性和市场敏锐性相结合的组织，将最有能力应对复杂性并抓住最具吸引力的机会。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 酵母生物工程在商业化生产高纯度CBG方面取得了快速进展
  • 消费者越来越偏好微剂量THCV产品来抑制食慾和提升能量。
  • 扩大第三方检测标准，以认证全球供应链中微量大麻素的纯度
  • 製药公司与大麻种植者结成策略联盟，共同开发新型次要大麻素疗法
  • 欧盟监管政策的改变简化了小剂量大麻素药物的核准程序。
  • 绿色萃取技术的创新旨在减少次要大麻素分离过程对环境的影响
  • 一种吸入式 CBG 输送系统的出现，该系统经过优化，可快速缓解成年消费者的焦虑情绪。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按产品类型分類的次要大麻素市场

  • 大麻色烯
  • 大麻酚
  • 大麻酚
  • Delta-8-THC
  • THCV

9. 按应用分類的次要大麻素市场

  • 医疗保健
    • 神经系统疾病
    • 疼痛管理
    • 皮肤病
    • 睡眠障碍
  • 休閒
    • 休閒用途
    • 感官增强
  • 健康
    • 营养补充品
    • 健身恢復
    • 缓解压力

第十章 按形式分類的次要大麻素市场

  • 饮料
    • 能量饮料
    • 注入水
    • 茶
  • 胶囊
  • 食用
    • 烘焙点心
    • 巧克力
    • 软糖
  • 油
  • 酊剂
  • 外用药物
    • 香脂
    • 奶油
    • 洗剂

第十一章 按分销管道分類的次要大麻素市场

  • 药局
    • 成人药房
    • 授权零售商
    • 医疗药房
  • 电子商务
    • 直接面向消费者
    • 市场
  • 药局
    • 医院药房
    • 零售药房
  • 健康商店

12. 依最终用途产业分類的次要大麻素市场

  • 化妆品
    • 护髮
    • 化妆品
    • 护肤
  • 饮食
    • 饮料
    • 糖果甜点
    • 小吃
  • 营养补充品
    • 机能性食品
    • 补充
  • 个人护理
  • 製药
    • 非处方药
    • 处方药

第十三章 依萃取法分類的次要大麻素市场

  • 二氧化碳萃取
    • 亚临界
    • 超临界
  • 乙醇萃取
  • 烃类萃取
    • 丁烷
    • 丙烷
  • 机械萃取

第十四章 各地区次要大麻素市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 按类别分類的次要大麻素市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国次要大麻素市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Folium Biosciences, Inc.
    • Mile High Labs, LLC
    • CV Sciences, Inc.
    • Botanacor Laboratories, Inc.
    • Bluebird Botanicals, LLC
    • Medical Marijuana, Inc.
    • ProVerde Laboratories, Inc.
    • ExtraktLAB, Inc.
    • Isodiol International Inc.
    • Scandinavian Biopharma AB
Product Code: MRR-3A2E844FF091

The Minor Cannabinoids Market is projected to grow by USD 35.86 billion at a CAGR of 8.41% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 18.79 billion
Estimated Year [2025] USD 20.39 billion
Forecast Year [2032] USD 35.86 billion
CAGR (%) 8.41%

The minor cannabinoids landscape has emerged from the shadows of mainstream cannabinoids to become a distinct field of scientific inquiry and commercial experimentation. These compounds, present in smaller concentrations in the cannabis plant, are attracting attention for their differentiated pharmacology, unique sensory profiles, and potential avenues for product innovation. As research deepens and extraction and formulation capabilities improve, developers, clinicians, and consumer brands are converging around opportunities to harness minor cannabinoids' nuanced effects.

Recent advances in analytical chemistry and targeted extraction have lowered technical barriers to isolating compounds such as cannabigerol and cannabichromene, while renewed clinical interest is prompting more rigorous investigation into therapeutic mechanisms. At the same time, consumer curiosity for alternatives to dominant cannabinoids is creating blueprints for novel products positioned within wellness, therapeutic, and recreational contexts. Investors and strategic buyers are watching closely as intellectual property, supply chain resilience, and regulatory clarity become decisive competitive factors.

Consequently, organizations are increasingly prioritizing cross-functional strategies that combine scientific validation, compliant commercialization pathways, and differentiated branding. Effective entry now requires synchronized efforts across R&D, regulatory affairs, manufacturing, and go-to-market functions, as the sector shifts from artisanal experimentation to structured product development and institutional investment.

How scientific advances regulatory recalibration and evolving consumer expectations are converging to transform commercialization pathways and strategic priorities across the industry

The industry is undergoing transformative shifts driven by parallel advances in science, regulatory evolution, and consumer demand. On the scientific front, improvements in analytical methods and precision extraction technologies have enabled the characterization and isolation of a broader range of minor cannabinoids than was previously feasible, uncovering distinct receptor interactions and therapeutic hypotheses. As a result, research programs are diversifying beyond the canonical cannabinoids toward molecules that offer subtler or complementary biological effects.

Regulatory landscapes are also shifting, with jurisdictions recalibrating frameworks to address new cannabinoids, adapt labeling and testing requirements, and balance public health concerns with commercial opportunity. These regulatory adjustments are prompting companies to invest in compliance infrastructure and to design products that can withstand greater scrutiny. Concurrently, consumer behavior is evolving: sophisticated wellness seekers and therapeutic users alike are seeking targeted formulations, transparent provenance, and scientifically grounded benefit claims.

In response, incumbents and new entrants are refining go-to-market strategies to emphasize evidence, supply chain traceability, and differentiated product narratives. Investors are increasingly focused on companies that can demonstrate reproducible extraction processes, robust analytical testing, and clear regulatory pathways. Taken together, these dynamics are accelerating the maturation of the sector from exploratory use cases to structured, scalable commercialization models.

Implications of United States tariff adjustments in 2025 on sourcing strategies supply chain resilience and manufacturing partnerships across the minor cannabinoids value chain

Tariff policy adjustments in the United States for 2025 are reshaping cross-border supply chain economics and prompting companies to reassess sourcing and manufacturing footprints. Firms that historically relied on international extraction, formulation, or ingredient supply are now recalculating landed costs, lead times, and inventory strategies in light of tariff shifts that affect the movement of raw botanical material, purified isolates, and finished goods components.

In response to these trade dynamics, many organizations are accelerating near-shoring initiatives, prioritizing domestic extraction capacity, or diversifying supplier networks to mitigate single-source exposure. These adjustments are not solely cost driven; they also reflect the strategic premium placed on supply chain resilience, quality control, and regulatory alignment, especially as domestic authorities increase scrutiny of test results and provenance documentation. Additionally, companies with vertically integrated operations are better positioned to absorb tariff impacts through internal value capture and by leveraging in-house compliance capabilities.

Moreover, the tariff environment is influencing partnership models: contract manufacturers and toll processors are recalibrating service offerings to support multinational clients facing incremental trade costs. Strategic buyers, licensors, and joint venture partners are increasingly evaluating whether collaborative manufacturing investments can neutralize tariff risk while preserving speed to market. Consequently, executives must incorporate tariff scenarios into sourcing decisions and contingency planning to maintain agility amid shifting trade economics.

Comprehensive segmentation framework revealing how product type application form distribution channel end use and extraction method jointly determine strategic product and regulatory choices

Segmentation by product type highlights distinct scientific and commercial considerations across cannabichromene, cannabigerol, cannabinol, delta-8-THC, and THCV, each carrying unique pharmacological profiles that inform formulation strategies and regulatory risk assessments. Likewise, segmentation by application differentiates clinical proof-points and consumer positioning: medical uses span neurological disorders, pain management, skin conditions, and sleep disorders; recreational applications emphasize leisure use and sensory enhancement; wellness focuses on dietary supplements, fitness recovery, and stress relief. These application axes directly influence claims architecture, evidence requirements, and channel suitability.

Form factors shape user experience and operational demands, with beverages, capsules, edibles, oil, tinctures, and topicals each presenting distinct formulation, stability, and dosing challenges. Within beverages, subsegments such as energy drinks, infused water, and teas demand attention to solubility and sensory masking; edibles including baked goods, chocolates, and gummies require robust stability protocols and consistent cannabinoid distribution; topicals represented by balms, creams, and lotions must address skin absorption and preservative systems. Distribution channel segmentation differentiates route-to-consumer approaches, from dispensaries that include adult-use, licensed retailers, and medical outlets, to e-commerce models structured around direct-to-consumer and marketplace strategies, and to pharmacies encompassing hospital and retail pharmacies, each imposing different regulatory and compliance touchpoints.

End use industry segmentation further refines opportunity mapping, with cosmetics spanning haircare, makeup, and skincare; food & beverages covering beverages, confectionery, and snacks; nutraceuticals split between functional foods and supplements; personal care and pharmaceuticals addressing OTC products and prescription drug pathways. Finally, extraction method segmentation-CO2 extraction with subcritical and supercritical modes, ethanol extraction, hydrocarbon extraction with butane and propane variants, and mechanical extraction-determines cost structures, impurity profiles, and scalability. Together, these segmentation lenses provide a multidimensional framework to guide product development, regulatory strategy, and commercial prioritization across the minor cannabinoids ecosystem.

Regional dynamics and regulatory heterogeneity across the Americas Europe Middle East Africa and Asia Pacific that shape tailored commercialization and compliance strategies

Regional dynamics are shaping differentiated pathways for research, regulation, and commercialization across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting distinct investor sentiment, consumer preferences, and policy environments. In the Americas, a mix of mature markets and rapidly evolving state-level regulations encourages innovation in both therapeutic and adult-use spaces, while commercial actors place emphasis on testing infrastructure, supply chain traceability, and retail channel optimization.

Across Europe, Middle East & Africa, regulatory heterogeneity and conservative public health frameworks often necessitate rigorous clinical evidence and clear product definitions; companies targeting these markets are focusing on pharmaceutical pathways, medical product registries, and collaborations with established healthcare providers. In contrast, Asia-Pacific presents a complex mosaic where cultural attitudes, import controls, and varying tolerance for cannabinoid products require carefully tailored go-to-market strategies. Many firms are prioritizing partnerships with local distributors, aligning formulations with regional ingredient standards, and designing educational programs to build consumer trust.

Taken together, these regional insights indicate that successful market approaches will be those that combine local regulatory intelligence with flexible manufacturing and distribution models. Strategic entrants must invest in region-specific compliance, local clinical or safety studies when required, and culturally attuned marketing to accelerate adoption while mitigating regulatory and reputational risk.

Key company capabilities and competitive differentiators including extraction expertise formulation scalability regulatory engagement and distribution reach that determine market leadership

Competitive positioning in the minor cannabinoids sector is defined by capabilities across R&D, extraction and formulation, regulatory affairs, and channel execution. Leading companies distinguish themselves through proprietary extraction know-how, validated analytical methodologies, and demonstrated ability to translate molecular profiles into consistent, reproducible products. Partnerships with academic institutions and contract research organizations are increasingly common as firms seek clinical validation and mechanistic understanding to support credible product claims.

Manufacturing capabilities remain a strategic differentiator: firms that can scale CO2 or ethanol extraction while maintaining rigorous impurity monitoring and batch reproducibility command a tactical advantage. At the same time, companies with flexible formulation platforms capable of addressing beverages, edibles, topicals, and oral dosage forms are better positioned to respond to shifting consumer preferences. Distribution strength, whether through licensed dispensaries, pharmacy channels, or robust direct-to-consumer e-commerce models, also differentiates players by enabling rapid market access and data capture for iterative product refinement.

Intellectual property and regulatory dossiers further separate market leaders from emerging contenders. Organizations that combine defensible process IP with proactive regulatory engagement achieve faster clearance for new products and reduce commercial risk. Collectively, these competencies form the basis for strategic alliances, M&A activity, and licensing transactions as companies seek to round out portfolios and accelerate time to meaningful revenue streams.

Actionable strategic priorities for industry leaders to translate scientific differentiation into resilient supply chains compliant commercialization and trusted consumer propositions

Industry leaders should prioritize an integrated strategy that aligns scientific validation, compliant manufacturing, and consumer education to convert technical potential into commercial results. First, invest in rigorous analytical and preclinical workstreams that establish product reproducibility and clarify mechanism-of-action narratives. These data assets will underpin credible marketing claims and reduce regulatory friction while supporting partnerships with clinical investigators and healthcare stakeholders.

Second, diversify extraction and manufacturing footprints to balance cost efficiency with supply chain resilience. Near-shoring, dual-sourcing, and investments in scalable CO2 or ethanol platforms will help mitigate trade exposure and ensure consistent quality. Third, adopt a channel-specific commercialization approach: design formulations and labeling for dispensaries and medical channels with the evidentiary rigor they demand, while tailoring wellness and recreational products to direct-to-consumer and retail channels that prioritize user experience and convenience.

Fourth, build regulatory intelligence capabilities to anticipate policy shifts and to engage proactively with regulators and standards bodies. Finally, cultivate brand trust through transparent sourcing disclosures, third-party testing, and consumer education programs that translate scientific findings into accessible benefit statements. By integrating these strategic pillars, organizations can convert technical differentiation into defensible market positions and sustainable growth.

Robust mixed methods research approach integrating stakeholder interviews technical literature regulatory review and synthesis to produce actionable operational and strategic insights

Research methodology for this analysis combined primary qualitative interviews with industry stakeholders, secondary literature synthesis, and technical review of publicly available regulatory guidance and peer-reviewed literature. Primary engagements included structured conversations with R&D leaders, supply chain executives, regulatory specialists, and commercial strategists to capture contemporary operational challenges and evolving priorities. These dialogues were designed to surface practical insights into extraction choices, formulation constraints, and go-to-market tradeoffs.

Secondary materials encompassed recent peer-reviewed studies on cannabinoid pharmacology, white papers from analytical laboratories on assay and stability methodologies, and jurisdictional policy updates relevant to product classification and labeling. Additionally, technical evaluation of extraction platforms and manufacturing processes informed assessments of scale, cost drivers, and impurity control requirements. Where gaps in published evidence existed, triangulation with subject-matter experts provided interpretive context and risk framing.

Throughout, the approach prioritized transparent documentation of assumptions and a conservative interpretation of emerging scientific signals. The resulting synthesis emphasizes operational considerations, regulatory pathways, and strategic implications rather than speculative commercial projections, ensuring that recommendations are actionable and grounded in observable industry practice.

Concluding synthesis highlighting the need for scientific rigor operational resilience and regionally adapted commercialization strategies to capture opportunity in the evolving landscape

In conclusion, minor cannabinoids represent a nuanced and rapidly evolving domain where scientific discovery, regulatory adaptation, and consumer demand intersect to create differentiated commercial pathways. The sector's maturation requires companies to invest in rigorous analytical capabilities, resilient supply chains, and tailored go-to-market strategies that align with regional regulatory frameworks and channel expectations. Those who secure credible scientific validation and demonstrate manufacturing consistency will be best positioned to translate technical differentiation into durable brand value.

Moreover, proactive regulatory engagement and diversified sourcing strategies will be essential to manage trade dynamics and policy uncertainty. Collaborative models that pair scientific institutions with commercial partners can accelerate evidence generation while spreading development risk. Finally, clear consumer education and transparent quality assurance practices will be central to building trust and enabling broader adoption across medical, wellness, and recreational use cases.

Organizations that adopt an integrated approach-melding research rigor, operational resilience, and market acuity-will be able to navigate complexity and seize the most compelling opportunities as the minor cannabinoids ecosystem continues to develop.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid advancements in yeast bioengineering to produce high purity CBG at commercial scale
  • 5.2. Growing consumer preference for microdosing THCV products targeting appetite suppression and energy
  • 5.3. Introduction of functional beverage lines fortified with CBN and CBD blends for enhanced sleep support
  • 5.4. Expansion of third-party testing standards to authenticate minor cannabinoid purity in global supply chains
  • 5.5. Strategic alliances between pharmaceutical companies and cannabis cultivators to develop novel minor cannabinoid therapies
  • 5.6. Regulatory updates in the European Union enabling streamlined approval pathways for minor cannabinoid pharmaceuticals
  • 5.7. Innovations in green extraction technologies reducing environmental impact of minor cannabinoid isolation processes
  • 5.8. Emergence of inhalable CBG delivery systems optimized for rapid onset anxiety relief in adult consumers

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Minor Cannabinoids Market, by Product Type

  • 8.1. Cannabichromene
  • 8.2. Cannabigerol
  • 8.3. Cannabinol
  • 8.4. Delta-8-Thc
  • 8.5. Thcv

9. Minor Cannabinoids Market, by Application

  • 9.1. Medical
    • 9.1.1. Neurological Disorders
    • 9.1.2. Pain Management
    • 9.1.3. Skin Conditions
    • 9.1.4. Sleep Disorders
  • 9.2. Recreational
    • 9.2.1. Leisure Use
    • 9.2.2. Sensory Enhancement
  • 9.3. Wellness
    • 9.3.1. Dietary Supplements
    • 9.3.2. Fitness Recovery
    • 9.3.3. Stress Relief

10. Minor Cannabinoids Market, by Form

  • 10.1. Beverages
    • 10.1.1. Energy Drinks
    • 10.1.2. Infused Water
    • 10.1.3. Teas
  • 10.2. Capsules
  • 10.3. Edibles
    • 10.3.1. Baked Goods
    • 10.3.2. Chocolates
    • 10.3.3. Gummies
  • 10.4. Oil
  • 10.5. Tinctures
  • 10.6. Topicals
    • 10.6.1. Balms
    • 10.6.2. Creams
    • 10.6.3. Lotions

11. Minor Cannabinoids Market, by Distribution Channel

  • 11.1. Dispensaries
    • 11.1.1. Adult-Use Dispensaries
    • 11.1.2. Licensed Retailers
    • 11.1.3. Medical Dispensaries
  • 11.2. E-Commerce
    • 11.2.1. Direct-To-Consumer
    • 11.2.2. Marketplaces
  • 11.3. Pharmacies
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Retail Pharmacies
  • 11.4. Wellness Stores

12. Minor Cannabinoids Market, by End Use Industry

  • 12.1. Cosmetics
    • 12.1.1. Haircare
    • 12.1.2. Makeup
    • 12.1.3. Skincare
  • 12.2. Food & Beverages
    • 12.2.1. Beverages
    • 12.2.2. Confectionery
    • 12.2.3. Snacks
  • 12.3. Nutraceuticals
    • 12.3.1. Functional Foods
    • 12.3.2. Supplements
  • 12.4. Personal Care
  • 12.5. Pharmaceuticals
    • 12.5.1. Otc Products
    • 12.5.2. Prescription Drugs

13. Minor Cannabinoids Market, by Extraction Method

  • 13.1. Co2 Extraction
    • 13.1.1. Subcritical
    • 13.1.2. Supercritical
  • 13.2. Ethanol Extraction
  • 13.3. Hydrocarbon Extraction
    • 13.3.1. Butane
    • 13.3.2. Propane
  • 13.4. Mechanical Extraction

14. Minor Cannabinoids Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Minor Cannabinoids Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Minor Cannabinoids Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Folium Biosciences, Inc.
    • 17.3.2. Mile High Labs, LLC
    • 17.3.3. CV Sciences, Inc.
    • 17.3.4. Botanacor Laboratories, Inc.
    • 17.3.5. Bluebird Botanicals, LLC
    • 17.3.6. Medical Marijuana, Inc.
    • 17.3.7. ProVerde Laboratories, Inc.
    • 17.3.8. ExtraktLAB, Inc.
    • 17.3.9. Isodiol International Inc.
    • 17.3.10. Scandinavian Biopharma AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL MINOR CANNABINOIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY END USE INDUSTRY, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY END USE INDUSTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY EXTRACTION METHOD, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY EXTRACTION METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS MINOR CANNABINOIDS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MINOR CANNABINOIDS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. MINOR CANNABINOIDS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. MINOR CANNABINOIDS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MINOR CANNABINOIDS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MINOR CANNABINOIDS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MINOR CANNABINOIDS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABICHROMENE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABICHROMENE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABICHROMENE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABICHROMENE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABICHROMENE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABICHROMENE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABIGEROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABIGEROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABIGEROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABIGEROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABIGEROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABIGEROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABINOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABINOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABINOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABINOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABINOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CANNABINOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DELTA-8-THC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DELTA-8-THC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DELTA-8-THC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DELTA-8-THC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DELTA-8-THC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DELTA-8-THC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY THCV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY THCV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY THCV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY THCV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY THCV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY THCV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SKIN CONDITIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SKIN CONDITIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SKIN CONDITIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SKIN CONDITIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SKIN CONDITIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SKIN CONDITIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SLEEP DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SLEEP DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SLEEP DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SLEEP DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SLEEP DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SLEEP DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RECREATIONAL, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RECREATIONAL, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RECREATIONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RECREATIONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RECREATIONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RECREATIONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RECREATIONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RECREATIONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LEISURE USE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LEISURE USE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LEISURE USE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LEISURE USE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LEISURE USE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LEISURE USE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SENSORY ENHANCEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SENSORY ENHANCEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SENSORY ENHANCEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SENSORY ENHANCEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SENSORY ENHANCEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SENSORY ENHANCEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DIETARY SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DIETARY SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DIETARY SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DIETARY SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FITNESS RECOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FITNESS RECOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FITNESS RECOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FITNESS RECOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FITNESS RECOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FITNESS RECOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY STRESS RELIEF, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY STRESS RELIEF, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY STRESS RELIEF, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY STRESS RELIEF, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY STRESS RELIEF, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY STRESS RELIEF, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY ENERGY DRINKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY ENERGY DRINKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY ENERGY DRINKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY ENERGY DRINKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY ENERGY DRINKS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY ENERGY DRINKS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY INFUSED WATER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY INFUSED WATER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY INFUSED WATER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY INFUSED WATER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY INFUSED WATER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY INFUSED WATER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TEAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TEAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TEAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TEAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TEAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TEAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY EDIBLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BAKED GOODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BAKED GOODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BAKED GOODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BAKED GOODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BAKED GOODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BAKED GOODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CHOCOLATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CHOCOLATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CHOCOLATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CHOCOLATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CHOCOLATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CHOCOLATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY GUMMIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY GUMMIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY GUMMIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY GUMMIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY GUMMIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY GUMMIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY OIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY OIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY OIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY OIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY OIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY OIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TINCTURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TINCTURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TINCTURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TINCTURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TINCTURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TINCTURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TOPICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TOPICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TOPICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TOPICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TOPICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY TOPICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BALMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BALMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BALMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BALMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BALMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BALMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LOTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LOTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LOTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LOTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LOTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LOTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DISPENSARIES, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DISPENSARIES, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DISPENSARIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DISPENSARIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DISPENSARIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DISPENSARIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DISPENSARIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DISPENSARIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY ADULT-USE DISPENSARIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY ADULT-USE DISPENSARIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY ADULT-USE DISPENSARIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY ADULT-USE DISPENSARIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY ADULT-USE DISPENSARIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY ADULT-USE DISPENSARIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LICENSED RETAILERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LICENSED RETAILERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LICENSED RETAILERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LICENSED RETAILERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LICENSED RETAILERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY LICENSED RETAILERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL DISPENSARIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL DISPENSARIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL DISPENSARIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL DISPENSARIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL DISPENSARIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MEDICAL DISPENSARIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY E-COMMERCE, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY E-COMMERCE, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY E-COMMERCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY E-COMMERCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY E-COMMERCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY E-COMMERCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY E-COMMERCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DIRECT-TO-CONSUMER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DIRECT-TO-CONSUMER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DIRECT-TO-CONSUMER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DIRECT-TO-CONSUMER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DIRECT-TO-CONSUMER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY DIRECT-TO-CONSUMER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MARKETPLACES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MARKETPLACES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MARKETPLACES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MARKETPLACES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MARKETPLACES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MARKETPLACES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS STORES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS STORES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS STORES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS STORES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS STORES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY WELLNESS STORES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY END USE INDUSTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY END USE INDUSTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY COSMETICS, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY COSMETICS, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY COSMETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY COSMETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY COSMETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY COSMETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY COSMETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY COSMETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY HAIRCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY HAIRCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY HAIRCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY HAIRCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY HAIRCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY HAIRCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MAKEUP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MAKEUP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MAKEUP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MAKEUP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MAKEUP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY MAKEUP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SKINCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SKINCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SKINCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SKINCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 315. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SKINCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 316. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY SKINCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 317. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FOOD & BEVERAGES, 2018-2024 (USD MILLION)
  • TABLE 318. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FOOD & BEVERAGES, 2025-2032 (USD MILLION)
  • TABLE 319. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FOOD & BEVERAGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 320. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FOOD & BEVERAGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 321. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FOOD & BEVERAGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 322. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FOOD & BEVERAGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 323. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FOOD & BEVERAGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 324. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY FOOD & BEVERAGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 325. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 326. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 327. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 328. GLOBAL MINOR CANNABINOIDS MARKET SIZE, BY BEVERAGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 329. GLOBAL MINOR CANNABINOIDS MA